About the Authors
- Andrea Giustina
-
* E-mail: a.giustina@libero.it
Affiliation Chair of Endocrinology, Department of Medical and Surgical Sciences, University of Brescia, Montichiari Hospital, Brescia, Italy
- Gherardo Mazziotti
-
Affiliations Chair of Endocrinology, Department of Medical and Surgical Sciences, University of Brescia, Montichiari Hospital, Brescia, Italy, Department of Medicine, Endocrine Unit, Azienda Ospedaliera “Carlo Poma”, Mantova, Italy
- Valter Torri
-
Affiliation Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
- Maurizio Spinello
-
Affiliation Novartis Farma, Origgio, Varese, Italy
- Irene Floriani
-
Affiliation Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
- Shlomo Melmed
-
Affiliation Pituitary Center, Cedars-Sinai Medical Center, Los Angeles, California, United States of America
Competing Interests
AG is a consultant for Ipsen and Novartis and lecturer for Pfizer and Italfarmaco. GM is a consultant for Novartis and received lecture fees from Ipsen. VT is consultant for Novartis. IF is consultant for Novartis. MS is Novartis Farma employee. SM is a consultant for Novartis and Chiasma, and receives research grants from Novartis, Pfizer and Ipsen. The authors declare that the article is actually concerned with the Novartis product Octreotide. The authors declare that the following authors are consultant for Novartis: AG (also consultant for Ipsen and lecturer for Pfizer and Italfarmaco), GM (also lecturer for Ipsen), VT, IF and SM (consultant also Chiasma, and receives research grants from Pfizer and Ipsen. The authors declare that the above mentioned relationships did not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: AG GM SM. Performed the experiments: GM VT IF. Analyzed the data: VT IF. Contributed reagents/materials/analysis tools: MS. Wrote the paper: AG GM SM.